Clinical, imaging, and management features of symptomatic carotid web: Insight from CAROWEB registry.

Carotid web Caucasian carotid endarterectomy carotid stenting ischemic stroke transient ischemic attack

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
09 Oct 2023
Historique:
pubmed: 19 9 2023
medline: 19 9 2023
entrez: 19 9 2023
Statut: aheadofprint

Résumé

Although carotid web (CaW) is increasingly diagnosed as a cause of cryptogenic stroke, data are still limited to monocentric small sample cohort. To broaden knowledge on symptomatic CaW, CAROWEB registry has been recently implemented. In a large cohort of symptomatic CaW patients, we described epidemiologic characteristics, admission clinical and imaging features, and the current management including the secondary preventive strategy choice made in comprehensive French Stroke Units. CAROWEB is an ongoing French observational multicenter registry enrolling consecutive CaW patients diagnosed after an ipsilateral ischemic stroke (IS) or transient ischemic attack (TIA). Submitted cases were validated by two experienced neurologist and neuroradiologist. Clinical, imaging, and management features were collected for this study. Between June 2019 and December 2021, 244 cases were submitted by 14 centers, 42 rejected, and 202 included (IS, 91.6%; TIA, 7.9%; retinal infarction, 0.5%; mean age, 50.8 ± 12.2 years; female, 62.9%; Caucasian, 47.5%; Afro-Caribbean, 20.3%). IS patients showed median (interquartile range (IQR)) admission National Institutes of Health Stroke Scale (NIHSS) score, 8 (2-15); intracranial artery occlusion, 71.8%; ipsilateral chronic cerebral infarction (CCI), 16.3%; and reperfusion treatment, 57.3%. CaW was not identified during the mechanical thrombectomy procedure in 30 of 85 (35.3%) patients. Secondary prevention was invasive in 55.6% (stenting, n = 80; surgery, n = 30). In multivariable analysis, the invasive therapeutic option was associated with ipsilateral CCI (odds ratio (OR): 4.24 (1.27-14.2), p = 0.019) and inversely associated with risk factors (OR: 0.47 (0.24-0.91), p = 0.025) and admission NIHSS score (OR: 0.93 (0.89-0.97), p = 0.001). CaW must be considered in all ethnic groups including Caucasians. Secondary prevention is heterogeneous in large French Stroke Centers. The absence of risk factors, milder severity strokes, and ipsilateral CCI were predictive variables of secondary invasive treatment. The high rate of invasive treatment suggests that medical treatment alone is deemed ineffective to avoid recurrence and emphasize the need of randomized trials.

Sections du résumé

BACKGROUND UNASSIGNED
Although carotid web (CaW) is increasingly diagnosed as a cause of cryptogenic stroke, data are still limited to monocentric small sample cohort. To broaden knowledge on symptomatic CaW, CAROWEB registry has been recently implemented.
AIMS UNASSIGNED
In a large cohort of symptomatic CaW patients, we described epidemiologic characteristics, admission clinical and imaging features, and the current management including the secondary preventive strategy choice made in comprehensive French Stroke Units.
METHODS UNASSIGNED
CAROWEB is an ongoing French observational multicenter registry enrolling consecutive CaW patients diagnosed after an ipsilateral ischemic stroke (IS) or transient ischemic attack (TIA). Submitted cases were validated by two experienced neurologist and neuroradiologist. Clinical, imaging, and management features were collected for this study.
RESULTS UNASSIGNED
Between June 2019 and December 2021, 244 cases were submitted by 14 centers, 42 rejected, and 202 included (IS, 91.6%; TIA, 7.9%; retinal infarction, 0.5%; mean age, 50.8 ± 12.2 years; female, 62.9%; Caucasian, 47.5%; Afro-Caribbean, 20.3%). IS patients showed median (interquartile range (IQR)) admission National Institutes of Health Stroke Scale (NIHSS) score, 8 (2-15); intracranial artery occlusion, 71.8%; ipsilateral chronic cerebral infarction (CCI), 16.3%; and reperfusion treatment, 57.3%. CaW was not identified during the mechanical thrombectomy procedure in 30 of 85 (35.3%) patients. Secondary prevention was invasive in 55.6% (stenting, n = 80; surgery, n = 30). In multivariable analysis, the invasive therapeutic option was associated with ipsilateral CCI (odds ratio (OR): 4.24 (1.27-14.2), p = 0.019) and inversely associated with risk factors (OR: 0.47 (0.24-0.91), p = 0.025) and admission NIHSS score (OR: 0.93 (0.89-0.97), p = 0.001).
CONCLUSION UNASSIGNED
CaW must be considered in all ethnic groups including Caucasians. Secondary prevention is heterogeneous in large French Stroke Centers. The absence of risk factors, milder severity strokes, and ipsilateral CCI were predictive variables of secondary invasive treatment. The high rate of invasive treatment suggests that medical treatment alone is deemed ineffective to avoid recurrence and emphasize the need of randomized trials.

Identifiants

pubmed: 37724713
doi: 10.1177/17474930231204343
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17474930231204343

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Stephane Olindo (S)

Service de Neurovasculaire, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Nicolas Gaillard (N)

Department of Neurology, Montpellier University Hospital, Montpellier, France.

Nicolas Chausson (N)

Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France.

Cedric Turpinat (C)

Department of Neurology, Montpellier University Hospital, Montpellier, France.

Cyril Dargazanli (C)

Department of Neuroradiology, Montpellier University Hospital, Montpellier, France.

Quentin Bourgeois-Beauvais (Q)

Department of Neurology, University Hospital of Martinique, Fort-de-France, France.

Aissatou Signate (A)

Department of Neurology, University Hospital of Martinique, Fort-de-France, France.

Julien Joux (J)

Department of Neurology, University Hospital of Martinique, Fort-de-France, France.

Mehdi Mejdoubi (M)

Department of Neuroradiology, University Hospital of Martinique, Fort-de-France, France.

Michel Piotin (M)

Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.

Mickael Obadia (M)

Department of Neurology, Rothschild Foundation Hospital, Paris, France.

Jean-Philippe Desilles (JP)

Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.

François Delvoye (F)

Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.

Quentin Holay (Q)

Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France.

Benjamin Gory (B)

Department of Interventional and Diagnostic Neuroradiology, University Hospital of Nancy, Nancy, France.

Sébastien Richard (S)

Department of Neurology, University Hospital of Nancy, Nancy, France.

Christian Denier (C)

Department of Neurology, CHU Kremlin Bicêtre, Paris, France.

Emmanuelle Robinet-Borgomano (E)

Department of Neurology, Hôpital de La Timone, Marseille University Hospital, Marseille, France.

Xavier Carle (X)

Department of Neurology, Hôpital de La Timone, Marseille University Hospital, Marseille, France.

Hubert Desal (H)

Department of Neuroradiology, Nantes University Hospital, Nantes, France.

Benoit Guillon (B)

Department of Neurology, Nantes University Hospital, Nantes, France.

Alain Viguier (A)

Department of Neurology, Toulouse University Hospital, Toulouse, France.

Matthias Lamy (M)

Department of Neurology, Poitiers University Hospital, Poitiers, France.

Fernando Pico (F)

Department of Neurology, Versailles Hospital, Versailles, France.

Anne Landais (A)

Department of Neurology, University Hospital of Guadeloupe, Pointe-à-Pitre, France.

Marion Boulanger (M)

Department of Neurology, Caen University Hospital, Caen, France.

Pauline Renou (P)

Stroke Unit, University Hospital of Bordeaux, Bordeaux, France.

Florent Gariel (F)

Department of Interventional and Diagnostic Neuroradiology, University Hospital of Bordeaux, Bordeaux, France.

Papaxanthos Jean (P)

Department of Interventional and Diagnostic Neuroradiology, University Hospital of Bordeaux, Bordeaux, France.

Lhermitte Yann (L)

Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France.

Lisa Papillon (L)

Stroke Unit, University Hospital of Bordeaux, Bordeaux, France.

Gaultier Marnat (G)

Department of Interventional and Diagnostic Neuroradiology, University Hospital of Bordeaux, Bordeaux, France.

Didier Smadja (D)

Department of Neurology, Sud Francilien Hospital, Corbeil-Essonnes, France.

Classifications MeSH